SCHAFFHAUSEN, Switzerland, April 5, 2017 /CNW/ - Occlutech, a leading innovator of implants to treat structural heart disease, today announced that it has obtained European CE Mark approval for its Perimembranous Ventricular Septal Defect (PmVSD) Occluder. The device is a specifically designed implant indicated for the minimally invasive closure of perimembranous ventricular septal defects.
Tor Peters, CEO of the Occlutech Group, commented: "The Occlutech PmVSD Occluder is the latest addition to our VSD occluder program. We are happy and proud to be able to provide patients and cardiologists with this innovative product as we expect our VSD occluder offering to provide improved therapeutic options for this patient population."
Perimembranous VSDs represent 70 - 80 % of all VSDs. Ventricular Septal Defects are the most common congenital cardiac abnormalities and they account for 30-60% of all congenital heart defects in newborns (about 2-6 VSDs per 1,000 births).
Occlutech's PmVSD Occluder consists of a flexible nitinol wire mesh with "shape-memory" properties and has been specifically designed for the closure of PmVSDs. Occlutech´s proprietary technology allows for the creation of products with unique properties regarding flexibility and adaptability.
Occlutech is a global leader in developing innovative products for the treatment of structural heart disease. The Company sells and markets ASD, PFO, PDA and VSD occluders, a range of specialized occlusion devices, including the paravalvar leak closure device Occlutech PLD, as well as, accessories in over 80 countries around the world. Occlutech has a number of innovative products in development and operates facilities in Germany, Turkey and Sweden.
For additional information about the Company's products, the Occlutech PmVSD, or to inquire about participation in our patient registries, please visit Occlutech's website at http://www.occlutech.com .